elenabs/istock via getty images

News

Teva launches authorized generic of Victoza in the US

Teva launches authorized generic of Victoza (liraglutide) in the United States, potentially reducing costs, improving access, and enhancing diabetes care outcomes.

By
  • Alivia Kaylor, MSc
Published: 25 Jun 2024

Teva Pharmaceuticals has announced the launch of an authorized generic version of Victoza (liraglutide, 1.8 mg injection) in the United States — a significant development in diabetes management. This move could have substantial implications for patients, healthcare providers, and the broader healthcare system.

Liraglutide, Victoza's active ingredient, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood sugar control in adults with type 2 diabetes. By mimicking the action of the naturally occurring hormone GLP-1, it helps stimulate insulin secretion and slow glucose absorption, effectively managing blood sugar levels. Since its approval in January 2010, Victoza has been a critical component of diabetes care, offering significant clinical benefits.

The introduction of this authorized generic version by Teva is poised to make this vital medication more accessible. Authorized generics are identical to brand-name drugs in dosage, safety, strength, quality, and performance characteristics. They are typically sold at a lower cost than the brand-name counterpart, offering a cost-effective alternative for patients and the healthcare system.

Impact on the US Healthcare System

  • Cost savings: Launching a generic version is expected to reduce the financial burden on patients and the healthcare system. Diabetes management is a significant cost driver in healthcare, with expensive medications being a substantial part of the expenses. The availability of a lower-cost generic option could lead to considerable savings for patients, insurance companies, and government healthcare programs.
  • Increased access: Affordability is a crucial factor in medication adherence. Lower prices can improve access to liraglutide for a broader patient population, including those who may have previously struggled to afford their prescriptions. Improved access can lead to better overall diabetes management, reducing the risk of complications and hospitalizations.
  • Encouraging competition: Introducing Teva’s authorized generic could stimulate market competition, potentially leading to further price reductions. When multiple manufacturers enter the market with generic versions, the cost often decreases, benefiting consumers the most.
  • Clinical outcomes: With more patients able to afford and access liraglutide, healthcare providers may see improved clinical outcomes in diabetes management. Effective blood sugar control is essential in preventing the long-term complications of diabetes, such as cardiovascular disease, kidney failure, and neuropathy. Enhanced medication adherence facilitated by lower costs can lead to better health outcomes and quality of life for patients.
  • Healthcare provider implications: Healthcare providers can confidently prescribe the authorized generic, knowing it offers the same efficacy and safety profile as the brand-name drug. This can simplify prescribing practices and ensure continuity of care as patients transition from brand-name Victoza to its generic counterpart without concerns about differences in treatment outcomes.

Teva’s launch of the authorized generic of Victoza represents a pivotal moment in diabetes care, with the potential to enhance patient access, reduce healthcare costs, and improve clinical outcomes. As the US healthcare system continues to grapple with the challenges of managing chronic diseases like diabetes, the availability of cost-effective, high-quality medications is a critical component in the journey toward more sustainable and equitable healthcare.

For industry stakeholders, this development underscores the importance of innovation and competition in driving down costs and improving patient care.

Next Steps

Dig Deeper on Pharmaceuticals